The Usage of Small RNAs for Cancer Diagnostics

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

About Dr. Ratislav Horos:
Dr. Rastislav Horos is Chief Technology Officer at Hummingbird Diagnostics GmbH in Heidelberg. His expertise includes next-generation sequencing, small RNA biology, assay development, and biomarker discovery from liquid biopsies. Prior to Hummingbird, he worked as a postdoctoral fellow and staff scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Dr. Horos holds a D.V.M. from the University of Veterinary Medicine and Pharmacy in Košice, Slovakia, and a Ph.D. in experimental hematology from Erasmus University Medical Center in Rotterdam, The Netherlands.

About Michael Weinstein:
Dr. Michael Weinstein is Director of Systems biology at Zymo Research and adjunct faculty at UCLA where he teaches genomics technology and bioinformatics. Starting as a wet-lab scientist ad transitioning to bioinformatics during the rise of NGS where he provided bioinformatic support to a broad set of labs at UCLA has enabled him to design solutions and troubleshoot across scientific fields and domains. His current focuses include RNA depletion applications, public health genomics, microbiome/metatranscriptome techniques, cell-free DNA applications, and bioinformatics education.

• Hummingbird’s unique approach that encompasses the analysis of whole blood to interrogate small RNA biomarkers from both the disease and host immune response.
• Zymo’s RiboFree technology enabling the analysis of bacterial RNAs in the context of infection.

Attend this webinar to learn how these exciting technologies are setting new standards for scientists in oncology and infection.